8-K filing — Alkermes plc. (ALKS)
Filed: 2026-08-12 AccNo: 0001193125-26-345901 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K/A filing — Alkermes plc. (ALKS)
Filed: 2026-08-03 AccNo: 0001193125-26-330564 Size: 188 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $61
Baird Maintains Outperform on Alkermes, Raises Price Target to $58
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.